emerg
virus
pose
major
threat
human
livestock
global
public
health
econom
burden
vaccin
remain
effect
tool
reduc
threat
yet
convent
cell
cultur
often
fail
produc
suffici
vaccin
dose
altern
cellcultur
base
vaccin
viruslik
particl
vlp
consid
highprior
vaccin
strategi
emerg
virus
vlp
repres
highli
order
repetit
structur
via
macromolecular
assembl
viral
protein
particul
natur
allow
effici
uptak
antigen
present
cell
stimul
innat
adapt
immun
respons
toward
enhanc
vaccin
efficaci
increas
research
activ
translat
opportun
necessit
advanc
design
vlp
new
bioprocess
modal
effici
costeffect
product
herein
describ
major
achiev
challeng
endeavor
respect
design
strategi
har
immunogen
potenti
product
platform
downstream
process
exemplari
case
develop
vlpbase
vaccin
infecti
diseas
lead
caus
death
among
children
adolesc
global
one
primari
caus
mortal
adult
andr
et
al
death
disproportion
burden
lowand
middleincom
countri
countri
highimpact
lowcost
public
health
intervent
remain
key
strategi
mitig
health
econom
burden
infecti
diseas
immun
remain
among
costeffect
measur
second
clean
water
howev
vaccin
unavail
inaccess
andor
unafford
popul
need
giers
et
al
therefor
invest
research
develop
deploy
vaccin
deliveri
technolog
emerg
reemerg
pathogen
like
yield
consider
dividend
global
health
vaccin
infecti
diseas
among
effect
global
public
health
mission
save
live
million
peopl
among
children
younger
age
everi
year
worldwid
giers
et
al
giers
et
al
howev
vaccin
challeng
solv
world
health
organ
warn
report
infecti
diseas
emerg
unpreced
rate
andr
et
al
sinc
infecti
diseas
newli
discov
includ
sar
mer
ebola
chikungunya
avian
flu
swine
flu
recent
zika
modern
world
peopl
travel
much
past
live
dens
popul
area
come
closer
contact
wild
anim
consequ
potenti
emerg
infecti
diseas
spread
rapidli
caus
global
epidem
becom
major
concern
pandem
influenza
swine
origin
prime
exampl
emerg
diseas
frequent
chang
influenza
viru
genom
caus
epidem
pandem
success
immun
evas
prior
infect
vaccin
moreov
potenti
zoonot
transmiss
domest
wild
anim
serv
mix
vessel
gener
novel
influenza
fact
pandem
influenza
turn
genet
reassort
among
four
differ
viral
speci
avian
swine
human
origin
shapshak
et
al
york
doni
although
direct
humantohuman
transmiss
offici
announc
highli
pathogen
avian
influenza
hpai
viru
remain
watch
list
especi
consid
extrem
high
mortal
among
human
help
meet
challeng
therapeut
prophylact
intervent
dearli
need
work
encompass
basic
research
direct
research
develop
evalu
vaccin
prevent
infect
agent
sever
challeng
develop
vaccin
et
al
bowick
mcauley
first
understand
pathogen
limit
protect
antigen
poorli
character
especi
newli
discov
virus
addit
highli
variabl
virus
virtual
imposs
predict
genet
variant
would
caus
next
outbreak
pandem
second
hard
find
appropri
anim
challeng
model
evalu
vaccin
efficaci
vaccin
candid
need
preclin
test
anim
model
safeti
immunogen
protect
efficaci
ideal
anim
model
wellknown
immun
system
similar
suscept
immun
respons
pathogen
natur
host
import
factor
choos
ideal
anim
model
price
size
possibl
use
larg
number
ethic
consider
howev
due
lack
knowledg
pathogen
eg
rout
infect
cellular
receptor
viral
entri
etc
ideal
anim
model
close
mimick
human
infect
hard
establish
third
emerg
virus
high
mortal
rate
treatment
prophylaxi
avail
must
manipul
high
biosafeti
condit
sometim
requir
facil
vaccin
manufactur
case
requir
product
target
virus
larg
quantiti
cell
cultur
similar
concern
appli
veterinari
vaccin
highli
contagi
virus
eg
foot
mouth
diseas
viru
fmdv
level
facil
requir
product
fourth
time
requir
develop
valid
produc
larg
scale
deliv
new
vaccin
ideal
short
possibl
could
facilit
use
wellknown
vaccin
platform
alreadi
test
valid
similar
pathogen
vaccin
use
control
ongo
outbreak
stockpil
advanc
produc
time
manner
provid
protect
prefer
singl
administr
yet
due
lack
adapt
cell
substrat
approv
regulatori
author
newli
isol
virus
often
difficult
imposs
produc
high
titer
enough
deliv
vaccin
time
manner
variou
type
vaccin
wide
spectrum
efficaci
safeti
develop
last
centuri
see
fig
convent
vaccin
inactiv
live
attenu
vaccin
requir
cultur
infecti
virus
cell
cultur
newli
discov
emerg
virus
convent
cell
cultur
often
fail
produc
suffici
vaccin
dose
test
immunogen
safeti
antigen
variabl
crossprotect
across
pathogen
therefor
strategi
would
circumv
cell
cultur
method
must
consid
first
viral
antigen
produc
recombin
synthet
peptidesprotein
pallist
et
al
turley
et
al
strategi
safe
product
process
involv
viral
replic
prospect
antigen
could
easili
modifi
enhanc
protect
howev
recombin
solubl
antigen
poorli
immunogen
would
requir
potent
adjuv
boost
enhanc
immunogen
second
strategi
involv
use
nucleic
acid
dna
recent
rna
immunogen
inocul
cdna
encod
viral
antigen
lead
uptak
express
cdna
antigenpres
cell
trigger
protect
immun
respons
powel
liu
et
al
fig
dna
vaccin
mani
advantag
primarili
product
bacteri
system
high
puriti
possibl
without
highlevel
biosafeti
requir
addit
lead
humor
cell
respons
introduct
replicon
plasmid
could
increas
immunogen
allow
limit
level
replic
cellular
uptak
yet
difficulti
deliveri
consequ
rel
low
level
immunogen
remain
improv
prefer
combin
adjuv
heterolog
primeboost
strategi
third
strategi
viral
vector
vaccin
gunther
sabchareon
et
al
sever
decad
recombin
virus
use
vector
protein
express
vaccin
purpos
virus
manipul
enhanc
safeti
immunogen
elimin
virul
factor
increas
code
capac
elimin
nonessenti
gene
chang
tropism
chang
envelop
protein
purpos
variou
type
vector
vaccin
platform
avail
major
concern
preexist
immun
viral
vector
often
compromis
vaccin
efficaci
fourth
recombin
bacteria
serv
vector
vivo
deliveri
antigen
dna
well
product
host
subunit
vaccin
pei
et
al
elicit
humor
cell
respons
inher
replicon
activ
increas
immunogen
purpos
sever
nontox
even
probiot
bacteria
avail
fig
differ
type
vlp
vlp
share
common
featur
selfassembl
particul
form
necessari
immun
stimul
lack
genet
materi
common
requir
vlp
base
vaccin
altern
vlp
could
also
use
deliveri
vehicl
nucleic
acid
protein
fifth
viruslik
particl
vlp
nanoparticl
peptid
multimer
assembl
provid
altern
vaccin
platform
akahata
et
al
steel
et
al
recombin
surfac
antigen
constitut
natur
virion
assembl
highli
order
conform
empti
particl
devoid
viral
genet
materi
featur
explor
way
increas
immunogen
viral
antigen
deliv
multimer
conform
prefer
vlp
mimick
morpholog
natur
infecti
virion
without
viral
deriv
genet
materi
vlp
highli
immunogen
proven
protect
immun
respons
safeti
profil
next
wave
technic
develop
vaccin
platform
discuss
vlp
detail
vlp
structur
resembl
infecti
virion
noninfecti
due
lack
viral
genom
requir
replic
kushnir
et
al
chen
lai
zeltin
still
possess
immunestimulatori
selfadjuv
properti
natur
virus
compris
capsid
protein
initi
immun
respons
vlp
distinct
featur
size
geometri
critic
abil
potent
activ
b
cell
elicit
robust
longlast
antibodi
respons
turn
two
featur
vlp
exploit
safe
effect
vaccin
fig
first
vlp
mostli
rang
nm
diamet
size
allow
free
entri
lymphat
vessel
passiv
drainag
subcapsular
area
within
lymph
node
recognit
uptak
variou
antigenpres
cell
manolova
et
al
vlp
traffic
b
cell
follicl
aid
specif
interact
complement
compon
natur
igm
antibodi
link
et
al
second
vlp
also
show
special
geometri
enabl
highli
activ
b
cell
epitop
present
multival
highli
repetit
outer
structur
vlp
thu
lead
crosslink
b
cell
receptor
interact
strongli
stimul
b
cell
induc
potent
longlast
antibodi
respons
jen
bachmann
bachmann
jen
zabel
et
al
furthermor
respons
overcom
b
cell
toler
allow
robust
antibodi
respons
induc
selfantigen
provid
technic
platform
therapeut
vaccin
metabol
diseas
bachmann
et
al
bachmann
zinkernagel
chackerian
et
al
vlp
stimul
innat
adapt
immun
respons
base
particul
structur
easili
recogn
absorb
antigenpres
cell
keller
et
al
sinc
develop
first
approv
recombin
vaccin
hepat
b
viru
vlp
demonstr
success
reliabl
vaccin
platform
tabl
vlp
divers
structur
classifi
capsidbas
nonenvelop
envelop
fig
capsidbas
envelop
vlp
singl
multilay
compos
singl
multipl
protein
among
simplest
nonenvelop
singlelay
vlp
human
papillomaviru
hpv
vlp
vaccin
simpl
vlp
produc
prokaryot
eukaryot
express
system
sometim
capsid
protein
simpl
vlp
recombinantli
produc
assembl
cellfre
environ
form
homogen
vlp
salunk
et
al
chen
et
al
bundi
et
al
bundi
swartz
nonenvelop
multiplecapsid
protein
vlp
complex
usual
produc
higher
eukaryot
host
yeast
rodriguezlima
et
al
li
et
al
insect
cell
palomar
et
al
fernand
et
al
plant
scotti
rybicki
express
system
allow
coexpress
differ
capsid
protein
complex
assembl
vlp
within
cell
envelop
vlp
assembl
matrix
protein
provid
molecular
scaffold
viral
antigen
embed
lipid
membran
differ
type
glycoprotein
embed
lipid
bilay
becom
target
immunolog
antigen
gener
neutral
antibodi
envelop
vlp
structur
uniform
challeng
character
influenza
vlp
wellstudi
exampl
envelop
vlp
kang
et
al
matrix
protein
glycoprotein
hemagglutinin
andor
neuraminidas
embed
lipid
bilay
vlp
function
variou
way
thu
wide
rang
applic
see
fig
first
vlp
function
immunogen
vaccin
cognat
viru
vlp
gener
unmodifi
compon
case
nonenvelop
hpv
vaccin
envelop
influenza
viru
vaccin
candid
galarza
et
al
second
novel
immunolog
antigen
display
vlp
novel
antigen
place
surfac
vlp
either
fusion
protein
chemic
conjug
peacey
et
al
jen
bachmann
therefor
vlp
effect
platform
exploit
gener
epitopebas
vlp
target
variou
diseas
plummer
manchest
heterolog
antigen
present
nonenvelop
vlp
achiev
fusion
small
epitop
larg
antigen
eg
hepat
b
viru
core
antigen
whitacr
et
al
envelop
vlp
heterolog
antigen
present
accomplish
insert
glycoprotein
eg
herp
simplex
viru
glycoprotein
insert
simian
immunodefici
viru
vlp
mcguigan
et
al
heterolog
head
domain
fusion
onto
transmembran
region
eg
vesicular
stomat
viru
glycoprotein
ectodomain
fuse
rabi
viru
glycoprotein
kato
et
al
third
vlp
recent
develop
deliveri
vector
nucleic
acid
protein
properti
viral
capsid
protein
allow
engin
vlp
encapsul
protein
molecul
nucleic
acid
exampl
packag
nucleic
acid
includ
nonenvelop
simian
viru
kawano
et
al
envelop
retroviru
vlp
keswani
et
al
likewis
heterolog
protein
encapsul
deliv
envelop
nonenvelop
vlp
dnaload
vlp
develop
gene
therapi
ramqvist
et
al
seow
wood
therapeut
vlp
encapsul
protein
drug
molecul
ashley
et
al
kaczmarczyk
et
al
comput
structur
model
bioinformat
techniqu
increasingli
appli
design
vlpbase
vaccin
ding
et
al
pankavich
ortoleva
et
al
current
complet
icosahedr
viru
capsid
structur
avail
viperdb
databas
http
viperdbscrippsedu
design
principl
multimolecular
assembl
could
deduc
data
gener
structur
comput
analys
well
highqual
render
inform
structur
analys
xray
crystallographi
cryoelectron
microscopi
carrillotripp
et
al
provid
major
tool
determin
crystal
structur
viral
capsid
grime
et
al
prasad
et
al
wynn
et
al
comput
analys
complement
empir
structur
analys
combin
provid
tool
ration
design
monom
expedit
assembl
vlp
follow
experiment
verif
kuroda
et
al
zhang
et
al
thu
design
vlpbase
vaccin
increasingli
benefit
protein
engin
monom
especi
consid
abil
intermolecular
interact
enhanc
comput
model
techniqu
requir
design
engin
vlp
novel
epitop
transplant
surfac
maxim
immunogen
potenti
particl
platform
technolog
target
antigen
must
display
high
densiti
surfac
vlp
differ
approach
tri
engin
tailor
vlp
molecular
scaffold
antigen
display
order
maxim
critic
featur
vlp
abl
display
foreign
antigen
variou
size
structur
composit
one
way
gener
recombin
fusion
foreign
antigen
insert
specif
site
within
viral
structur
protein
foreign
antigen
display
surfac
result
vlp
howev
peptid
insert
view
introduc
novel
epitop
often
advers
affect
fold
monom
consequ
fail
assembl
regular
compact
structur
often
result
misfold
amorph
aggreg
result
lower
immunogen
andor
vaccin
efficaci
problem
circumv
initi
preform
vlp
scaffold
foreign
antigen
epitop
subsequ
conjug
postproduct
modif
vlp
take
advantag
natur
occur
site
conjug
eg
amino
sulfhydryl
group
expos
vlp
surfac
hbcag
vlp
like
mani
vlp
foreign
antigen
insert
site
identifi
combin
empir
apporach
ration
design
base
structur
categor
first
comprehens
combinatori
approach
multipl
insert
site
compensatori
mutat
robust
screen
method
billaud
group
greatli
enhanc
success
rate
produc
chimer
woodchuck
hepat
viru
core
antigen
vlp
billaud
et
al
second
transform
subunit
vlp
thermodynam
stabl
conform
dramat
enhanc
success
rate
engin
vlp
novel
peptid
epitop
insert
third
approach
circumv
potenti
disrupt
fold
assembl
chemic
crosslink
antigen
preform
vlp
approach
potenti
increas
cost
product
decreas
scalabl
along
downstream
manufactur
process
allow
vlp
display
variou
antigen
includ
peptid
whole
protein
carbohydr
small
molecul
vlp
interact
variou
compon
immun
system
provok
protect
respons
receptor
entri
antigenpres
cell
molecular
compon
traffick
pathway
thu
vlpbase
vaccin
usual
provok
strong
immun
respons
modifi
vlp
structur
rel
degre
immun
respons
tune
balanc
induct
humor
cellmedi
immun
overal
impact
elicit
im
mune
respons
also
depend
intrins
halflif
particl
kind
adjuv
storni
et
al
manolova
et
al
link
et
al
anoth
critic
factor
consid
chemic
stabil
vlp
although
vlp
highli
stabl
case
vlp
type
withstand
wide
rang
temperatur
ph
condit
help
manufactur
storag
distribut
featur
particularli
import
develop
countri
cold
chain
readili
avail
addit
enhanc
thermal
stabil
vlp
reduc
product
cost
allow
longer
shelflif
also
reduc
deliveri
cost
requir
cold
storag
thermost
vlp
enhanc
structur
modif
introduct
intersubunit
disulfid
bond
ashcroft
et
al
fiedler
et
al
judici
choic
mutat
requir
minim
potenti
structur
perturb
otherwis
would
lead
amorph
intermolecular
aggreg
rather
regular
pack
vlp
compromis
vaccin
efficaci
develop
vlpbase
vaccin
seriou
consider
given
robust
faith
product
platform
enabl
deliveri
vaccin
time
reproduc
manner
signific
vlp
appreci
develop
nextgener
vaccin
sever
express
platform
produc
vlp
develop
includ
bacteria
escherichia
coli
yeast
insect
cell
mammalian
cell
plant
tabl
e
coli
express
system
easi
use
least
expens
major
drawback
bacteri
host
howev
e
coli
cytoplasm
provid
optim
milieu
fold
human
infect
viral
antigen
thu
rare
success
vlp
assembl
moreov
system
lack
posttransl
modif
capac
thu
use
limit
produc
simpl
vlp
nonenvelop
vlp
far
commerci
success
made
hepat
e
viru
hev
vaccin
base
chemic
refold
inclus
bodi
xiamen
innovax
biotech
co
ltd
wide
applic
vlp
vaccin
robust
express
platform
yet
develop
ensur
solubl
express
viral
antigen
amen
fold
selfassembl
novel
protein
fold
vehicl
recent
develop
could
implement
vlp
assembl
e
coli
fig
shown
rna
bind
could
affect
overal
kinet
network
protein
fold
pathway
favor
enhanc
fold
offpathway
aggreg
choi
et
al
choi
et
al
choi
et
al
addit
rna
bindingmedi
solubl
greatli
enhanc
increas
solubl
yield
passeng
protein
featur
could
use
implement
highthroughput
protein
express
rnainteract
mediat
fold
vehicl
provid
novel
express
platform
vlp
vaccin
eg
hpv
well
noroviru
unpublish
result
fascin
possibl
remain
rnabas
molecular
chaperon
protein
fold
could
extend
product
multicompon
vlp
yeast
system
popularli
use
produc
vlpbase
vaccin
exampl
hepat
b
viru
hbv
vaccin
engerixb
glaxosmithklin
human
papillomaviru
hpv
vaccin
gardasil
merck
co
inc
kim
kim
produc
recombin
yeast
yeast
system
elicit
high
express
easi
scaleup
unlik
e
coli
system
provid
posttransl
modif
express
protein
addit
yeast
low
risk
contamin
adventiti
agent
scaleup
product
yeast
mostli
appli
produc
vlp
simpl
structur
current
applic
extend
vlp
envelop
virus
furthermor
recent
found
yeast
system
enabl
vlp
produc
either
intracellularli
use
secret
pathway
enhanc
qualiti
quantiti
yeastbas
vlp
variou
factor
type
plasmid
promot
especi
secret
process
exit
yeast
cell
need
care
taken
account
bae
et
al
lee
et
al
han
et
al
baculovirusinsect
cell
mammaliancel
system
advantag
elicit
complet
posttransl
modif
includ
glycosyl
express
multipl
compon
vlp
rodriguezlima
et
al
vlpbase
vaccin
produc
use
system
includ
hbv
vaccin
genhevac
b
aventi
hpv
vaccin
cervarix
glaxosmithklin
system
expens
bacteri
system
downstream
process
usual
complex
bacteri
system
optim
downstream
recoveri
process
fig
would
afford
vlp
vaccin
hpv
vaccin
instanc
develop
countri
recent
plant
becom
newli
appreci
bioreactor
realiz
plant
molecular
pharm
work
factori
recombin
express
protein
interest
et
al
marsian
lomonossoff
innov
method
rapid
product
use
protein
plant
reli
transient
express
bypass
requir
tediou
transform
regener
step
strategi
appli
produc
viral
coat
protein
assembl
vlp
protein
product
system
plant
costeffect
highli
scalabl
manufactur
requir
water
carbon
dioxid
inorgan
nutrient
sunlight
growth
twyman
et
al
lico
et
al
paul
et
al
marsian
lomonossoff
plant
express
system
provid
complex
distinct
protein
assembl
posttransl
modif
mammaliancel
system
show
highlevel
immunogen
glycosyl
yeast
insect
cell
limit
simpl
inconsist
glycoform
wherea
plant
gener
wide
varieti
glycosyl
type
chen
lai
recent
success
genet
engin
plant
support
human
glycosyl
plant
line
hold
great
potenti
applic
marsian
lomonossoff
furthermor
unlik
mammalian
cell
cultur
bring
low
risk
contamin
deriv
endotoxin
mammalian
pathogen
vlp
product
recombin
host
invari
associ
numer
impur
cell
substrat
manufactur
process
us
food
drug
administr
fda
summar
impur
two
subgroup
processrel
productrel
contamin
us
fda
processrel
contamin
predominantli
attribut
host
cell
impur
cell
cell
debri
host
cellderiv
protein
dna
proteas
endotoxin
polysaccharid
lipid
impur
intrins
product
process
media
compon
antifoam
reagent
potenti
hazard
supplement
upstream
downstream
process
stabil
excipi
proteas
nucleas
list
inact
ingredi
allow
final
drug
formul
provid
fda
http
wwwaccessdatafdagovscriptscderiigindexcfm
world
health
organ
state
qualiti
monitor
final
vlpbase
vaccin
bulk
includ
among
other
test
steril
bacteria
fungi
test
viru
clearanc
summari
vaccin
composit
protein
lipid
polysaccharid
control
residu
dna
protein
endotoxin
content
determin
protein
puriti
sdspage
similar
descript
residu
chemic
sever
factor
express
host
cellular
environ
type
target
viral
protein
viru
subtyp
exert
influenc
qualiti
vivoassembl
vlp
recombin
system
mach
et
al
practic
difficult
suffici
control
factor
vlp
assembl
vivo
altern
therefor
disassembl
reassembl
vitro
develop
optim
sever
vlp
mccarthi
et
al
ren
et
al
xing
et
al
link
et
al
et
al
disassembl
reassembl
vitro
allow
easi
control
encapsul
host
cell
impur
lead
increas
homogen
stabil
reactiv
vlp
zhao
et
al
zhao
et
al
molecular
dynam
simul
enabl
better
understand
assembl
mechan
predict
qualiti
newli
design
vlp
construct
zhang
et
al
productrel
contamin
includ
vlp
aggreg
form
upstream
downstream
process
model
competit
aggreg
selfassembl
order
stuructur
develop
shi
et
al
ding
et
al
sanchezrodriguez
et
al
properli
implement
may
help
enhanc
qualiti
purif
yield
final
bulk
product
need
meet
desir
puriti
criteria
recombin
vlp
effio
hubbuch
downstream
purif
process
rang
initi
product
isol
cell
concentr
clarif
captur
intermedi
purif
polish
molecul
interest
effio
hubbuch
method
choic
process
includ
chromatographi
filtrat
integr
purif
techniqu
processrel
contamin
need
separ
particularli
begin
process
wherea
productrel
contamin
residu
processrel
impur
remov
prefer
final
polish
step
past
process
develop
optim
downstream
process
mostli
depend
empir
approach
trial
error
virtu
recent
develop
emerg
technolog
fda
implement
qualiti
design
qbd
process
analyt
technolog
pat
biopharmaceut
product
idea
approach
develop
better
knowledg
control
product
manufactur
process
use
pat
method
ration
develop
strategi
pat
method
includ
onlin
highperform
liquid
chromatographi
hplc
system
lightscatt
techniqu
enabl
process
surveil
control
unit
oper
realtim
rathor
winkl
yu
et
al
monitor
size
vlp
manufactur
especi
import
qualiti
control
vlpbase
vaccin
new
ration
develop
strategi
biopharmaceut
product
involv
approach
design
experi
doe
scaledown
highthroughput
experiment
process
model
new
strategi
technolog
vlp
purif
downstream
process
recent
arisen
effio
hubbuch
ultracentrifug
step
progress
replac
scalabl
chromatographi
filtrat
unit
oper
new
stationari
phase
altern
method
aqueou
twophas
extract
precipit
expand
bed
adsorpt
chromatographi
increasingli
use
norovirus
common
caus
nonbacteri
acut
gastroenter
human
worldwid
patel
et
al
hall
et
al
highli
infecti
virus
recent
refer
perfect
human
pathogen
sinc
viru
highli
stabl
environ
infecti
low
dose
moder
virul
yet
rapidli
shed
larg
quantiti
host
follow
natur
infect
addit
viru
antigen
divers
evolv
induc
limit
immun
natur
infect
hall
lack
proper
cell
cultur
method
anim
infect
model
pose
challeng
develop
vaccin
altern
cell
cultur
method
vlp
enabl
signific
progress
toward
effect
vaccin
candid
design
protect
multipl
circul
noroviru
strain
vaccin
noroviru
vlp
vaccin
shown
induc
antibodi
block
virusderiv
vlp
carbohydr
bind
protect
homolog
viral
challeng
clinic
studi
first
find
recombin
noroviru
capsid
sequenc
express
selfassembl
vlp
morpholog
similar
infect
virion
jiang
et
al
led
extens
use
vlp
understand
noroviru
structur
immunogen
receptorbind
activ
case
norovirus
inabl
propag
virus
cell
cultur
preclud
develop
liveattenu
inactiv
vaccin
candid
thu
sever
express
system
develop
product
noroviru
vlp
includ
yeast
baculovirusinfect
insect
cell
transgen
plant
initi
method
describ
noroviru
vlp
product
typic
involv
smallvolum
cell
cultur
vlp
purif
subsequ
carri
centrifug
andor
sucros
densiti
gradient
fraction
jiang
et
al
ausar
et
al
huhti
et
al
although
product
method
gener
suffici
level
materi
gener
character
anim
immunogen
studi
robust
scalabl
product
method
requir
human
clinic
trial
recent
product
purif
develop
focus
commerci
scalabl
unit
process
includ
bioreactor
product
column
chromatographi
ultrafiltrationdiafiltr
ufdf
kissmann
et
al
taylor
koho
et
al
largescal
bioprocess
plantderiv
norwalk
vlp
accomplish
use
phdepend
precipit
process
contamin
follow
ufdf
clarifi
harvest
fraction
chromatograph
purif
anionexchang
chromatographi
lai
chen
purifi
protein
properli
assembl
stabl
vlp
contain
low
level
residu
host
cell
protein
nucleic
acid
impur
stabil
norwalk
vlp
structur
vaccin
formul
enhanc
carbohydr
excipi
kissmann
et
al
futur
develop
lowcost
largescal
manufactur
process
prefer
use
bacteri
host
fig
requir
deliveri
unmet
need
vaccin
lowor
middleincom
countri
success
launch
first
recombin
vaccin
produc
yeast
product
platform
vlpbase
hepat
b
viru
vaccin
extend
plant
mechtcheriakova
et
al
demonstr
monomer
form
core
antigen
hbcag
express
spontan
form
corelik
particl
differ
heterolog
express
system
includ
bacteria
plant
hbc
particl
spiki
surfac
repetit
present
antigen
determin
show
strong
inher
immunogen
use
display
foreign
peptid
peyret
et
al
use
hbcag
dimer
produc
tandem
fusion
two
hbcag
open
read
frame
carrier
system
antigen
develop
tandem
core
system
still
selfassembl
corelik
particl
use
display
correctli
fold
gfp
nanobodi
surfac
turn
use
bind
cognat
antigen
therefor
possibl
display
whole
protein
particl
surfac
papillomavirus
nonenvelop
tumorinduc
dna
virus
serotyp
mostli
infect
human
account
human
cancer
et
al
two
type
hpv
vlp
vaccin
base
selfassembl
major
capsid
protein
express
yeast
insect
cell
current
market
rybicki
altern
yeastor
insect
cellbas
product
lowcost
plantbas
vaccin
develop
success
express
vlp
et
al
last
decad
signific
advanc
made
design
manufactur
vlp
vaccin
vital
altern
tradit
cellcultur
vaccin
capit
strong
immun
stimul
intrins
particul
form
immunogen
continu
research
focus
engin
vlp
assembl
enhanc
particl
stabil
divers
antigen
display
surfac
vlp
although
vlpbase
vaccin
reach
market
vlpbase
vaccin
emerg
virus
current
avail
yet
great
expect
sever
vlp
vaccin
base
posit
result
clinic
trial
technic
challeng
still
remain
howev
compar
vlp
made
singl
compon
eg
noroviru
hpv
assembl
viral
capsid
requir
multicompon
eg
fmdv
hfmv
complex
understand
fold
individu
monom
complex
involv
multimer
macromolecular
assembl
well
enabl
protein
fold
technolog
requir
downstream
process
especi
envelop
vlp
purif
vlp
baculovir
particl
similar
size
biophys
charact
still
pose
daunt
challeng
meet
regulatori
requir
safeti
issu
proper
inactiv
contamin
baculovirion
without
sacrif
immunogen
vlp
also
combin
despit
huddl
recombin
vlp
vaccin
platform
altern
cellcultur
method
would
emerg
forese
futur
major
manufactur
platform
vaccin
combat
emerg
reemerg
infecti
diseas
